Brief: Caladrius Biosciences Says Cend Therapeutics Treated First Patient In Phase 2B Trial Of Cend-1
09/06/2022 13:04
June 9 (Reuters) - Caladrius Biosciences Inc CLBS.O :
* CALADRIUS BIOSCIENCES ANNOUNCES MERGER PARTNER, CEND
THERAPEUTICS, HAS TREATED FIRST PATIENT IN PHASE 2B TRIAL OF
CEND-1 IN COLLABORATION WITH AUSTRALASIAN GASTRO-INTESTINAL
CANCER TRIALS GROUP
Source text for Eikon: ID:nGNX8bFVQj
Further company coverage: CLBS.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Lisata Therapeutics
See all newsBrief: Lisata Therapeutics Appoints Jeff Farrow To Board Of Directors
Brief: Lisata Therapeutics Announces New Method Of Use Patent Granted For Certepetide In The Treatment Of Pancreatic Cancer And Other Solid Tumors
NASDAQ RESUMED AT 09:55 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:55 AM
U.S. STOCKS ON THE MOVE -Expeditors International, Waters, Ameresco